首页> 美国卫生研究院文献>Springer Open Choice >Comparative pharmacokinetics safety and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

【2h】

Comparative pharmacokinetics safety and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

机译：儿科清髓性治疗后高危神经母细胞瘤小儿ch14.18两种来源的比较药代动力学安全性和耐受性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeDinutuximab (Unituxin™; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma. United Therapeutics Corporation (UTC) assumed ch14.18 production from the National Cancer Institute (NCI); this study evaluates pharmacokinetic comparability, safety, and tolerability of UTC and NCI products.

机译：目的作为抗高密度神经母细胞瘤巩固后治疗的一部分，抗双唾液酸神经节苷脂的单克隆抗体Dinutuximab（Unituxin™； ch14.18）提高了生存率。 United Therapeutics Corporation（UTC）假定国家癌症研究所（NCI）生产ch14.18；这项研究评估了UTC和NCI产品的药代动力学可比性，安全性和耐受性。

著录项

期刊名称 Springer Open Choice
作者
Araz Marachelian; Ami Desai; Frank Balis; Howard Katzenstein; Muna Qayed; Michael Armstrong; Kathleen A. Neville; Susan L. Cohn; Mark Bush; Rudy Gunawan; Allison Pecha Lim; Malcolm A. Smith; L. Mary Smith;
展开▼
作者单位

展开▼
年(卷),期 -1(77),-1
年度 -1
页码 405–412
总页数 8
原文格式 PDF
正文语种
中图分类外科学;
关键词
ch14.18 Dinutuximab Pharmacokinetics Safety Tolerability Unituxin;

机译：ch14.18;Dinutuximab;药代动力学;安全性;耐受性;Unituxin;

相似文献

外文文献
中文文献
专利

1. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy [J] . Marachelian Araz, Desai Ami, Balis Frank, Cancer chemotherapy and pharmacology. . 2016,第2期

机译：小儿清髓性治疗后高危神经母细胞瘤小儿ch14.18两种来源的比较药代动力学，安全性和耐受性
2. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212) [J] . Greengard Emily, Mosse Yael P., Liu Xiaowei, Cancer chemotherapy and pharmacology. . 2020,第6期

机译：Crizotinib的安全性，耐受性和药代动力学与细胞毒性化疗组合难治性固体肿瘤或血栓性大细胞淋巴瘤（ALCL）：儿童肿瘤组阶段1财团研究（ADVL1212）
3. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy‐induced nausea and vomiting in pediatric cancer patients [J] . Mora Jaume, Valero Miguel, DiCristina Cara, Pediatric blood & cancer . 2019,第6期

机译：FOSAPREPITANT用于预防化疗诱导的恶心和呕吐在儿科癌症患者中的药代动力学/药效学和耐受性
4. Therapy of Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Efficacy, Tolerability, and Safety of a New Nanofiltered Intravenous Immunoglobulin [C] . H.-H. Wolf, S. Davies, G. Smith, European Haematology Association . 2002

机译：慢性免疫血小板减少症患者的治疗患者（ITP）：一种新的纳米过滤静脉内免疫球蛋白的疗效，耐受性和安全性
5. Intranasal and rectal diazepam for rescue therapy: Assessment of pharmacokinetics and tolerability. [D] . Ivaturi, Vijay Deep. 2010

机译：鼻内和直肠地西epa用于抢救治疗：药代动力学和耐受性评估。
6. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 [O] . M. Fevzi Ozkaynak, Andrew L. Gilman, Wendy B. London, -1

机译：更正：高度清净性神经母细胞瘤患者接受清髓治疗后嵌合抗体14.18与GM-CSFIL-2和异维A酸的综合安全性试验：儿童肿瘤学小组研究ANBL0931
7. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy [O] . Araz Marachelian, Ami Desai, Frank Balis, 2016

机译：儿科清髓性治疗后高危神经母细胞瘤小儿ch14.18两种来源的比较药代动力学，安全性和耐受性

Comparative pharmacokinetics safety and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

摘要

著录项

相似文献

相关主题

期刊订阅